真实世界中医源性改善速度:PSSD日记12周次要结局
PSoHO是一项国际前瞻性非干预研究,纳入1654例中重度银屑病患者,使用PSSD日记(0-10分)每周评估症状和体征。抗IL-17A生物制剂队列自第1周起至12周在PSSD汇总评分改善和达到临床有意义改善的患者比例上均显著优于其他生物制剂队列。抗IL-17A生物制剂(尤其艾克司单抗)在真实世界中带来快速且持续的患者报告改善。
要点
- 抗IL-17A队列自第1周起PSSD评分改善显著大于其他生物制剂队列,持续至12周。
- 抗IL-17A队列达到临床有意义改善的患者比例高于其他生物制剂队列。
- 第2周PSSD早期临床有意义改善与第12周PASI100缓解存在关联。
核心结论
- 在真实世界环境中,抗IL-17A生物制剂(尤其艾克司单抗)较其他生物制剂带来快速且持续的患者报告银屑病症状和体征改善。
研究设计与样本
- PSoHO为国际前瞻性非干预研究,比较抗IL-17A生物制剂与其他生物制剂,并进行艾克司单抗与五种单个生物制剂的两两比较,纳入患者n=1654。
主要发现
- 自第1周起至12周,抗IL-17A队列PSSD汇总评分改善显著大于其他生物制剂队列,达到临床有意义改善的患者比例也更高。
- PSSD评分越低,报告银屑病不再影响生活质量(DLQI 0,1)和达到高水平临床应答(PASI100)的患者比例越高。
- 第2周PSSD评分早期临床有意义改善与第12周PASI100评分之间存在关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapid skin improvement is a key treatment goal of patients with moderate-to-severe psoriasis (PsO). OBJECTIVES: To compare the speed of clinical improvement of approved biologics on the symptoms and signs of psoriasis assessed by patients using the validated Psoriasis Symptoms and Signs Diary (PSSD) through 12 weeks. METHODS: Psoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non-interventional study that compares the effectiveness of anti-interleukin (IL)-17A biologics versus other biologics, together with pairwise comparisons of ixekizumab versus five individual biologics in patients with PsO. Using the PSSD 7-day recall period, patients assessed the symptoms (itch, skin tightness, burning, stinging and pain) and signs (dryness, cracking, scaling, shedding/flaking, redness and bleeding) of their psoriasis (0-10). Symptom and sign summary scores (0-100) are derived from the average of individual scores. Percentage change in summary scores and proportion of patients with clinically meaningful improvements (CMI) in PSSD summary and individual scores are evaluated weekly. Longitudinal PSSD data are reported as observed with treatment comparisons analysed using mixed model for repeated measures (MMRM) and generalized linear mixed models (GLMM). RESULTS: Across cohorts and treatments, eligible patients (n = 1654) had comparable baseline PSSD scores. From Week 1, the anti-IL-17A cohort achieved significantly larger score improvements in PSSD summary scores and a higher proportion of patients showed CMIs compared to the other biologics cohort through 12 weeks. Lower PSSD scores were associated with a greater proportion of patients reporting their psoriasis as no longer impacting their quality-of-life (DLQI 0,1) and a high level of clinical response (PASI100). Results also indicate a relationship between an early CMI in PSSD score at Week 2 and PASI100 score at Week 12. CONCLUSIONS: Treatment with anti-IL-17A biologics, particularly ixekizumab, resulted in rapid and sustained patient-reported improvements in psoriasis symptoms and signs compared with other biologics in a real-world setting.
引用
- Reich A, Pinter A, Maul JT, et al. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. J Eur Acad Dermatol Venereol. 2023. PMID: 37147855. doi:10.1111/jdv.19161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。